NAV

OT-551

Identification

Generic Name
OT-551
DrugBank Accession Number
DB05650
Background

OT-551 is a novel small molecule that is topically dosed in an eye drop and has the unique ability to penetrate cell membranes and reach both the front and the back of the eye. It is intended to treat Age-related macular Degeneration (AMD), and preclinical research results indicate additional uses for OT-551, including treatment of early stage and advanced dry age-related macular degeneration (AMD) by protecting against retina photoreceptor cell death and inhibiting angiogenesis, the growth of small blood vessels leading to the wet-form of AMD. A leading cause of vision loss, AMD affects approximately 10 million Americans.

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 241.331
Monoisotopic: 241.167793605
Chemical Formula
C13H23NO3
Synonyms
Not Available
External IDs
  • OT 551
  • OT-551
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Investigated for use/treatment in cataracts, eye disorders/infections, glaucoma, and macular degeneration.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

OT-551, which has been shown to be a potent catalytic antioxidant, recently completed a Phase 1 safety and comfort study in healthy volunteers.

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as piperidines. These are compounds containing a piperidine ring, which is a saturated aliphatic six-member ring with one nitrogen atom and five carbon atoms.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Piperidines
Sub Class
Not Available
Direct Parent
Piperidines
Alternative Parents
Cyclopropanecarboxylic acids and derivatives / Carboxylic acid esters / N-organohydroxylamines / Monocarboxylic acids and derivatives / Azacyclic compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Aliphatic heteromonocyclic compound / Azacycle / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Cyclopropanecarboxylic acid or derivatives / Hydrocarbon derivative / Monocarboxylic acid or derivatives / N-organohydroxylamine / Organic nitrogen compound
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
DZ02S3A31N
CAS number
627085-11-4
InChI Key
ZWEXEKJLDHNLLA-UHFFFAOYSA-N
InChI
InChI=1S/C13H23NO3/c1-12(2)7-10(8-13(3,4)14(12)16)17-11(15)9-5-6-9/h9-10,16H,5-8H2,1-4H3
IUPAC Name
1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl cyclopropanecarboxylate
SMILES
CC1(C)CC(CC(C)(C)N1O)OC(=O)C1CC1

References

General References
Not Available
PubChem Compound
10131000
PubChem Substance
347827737
ChemSpider
8306515
ZINC
ZINC000034279410

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentAge - Related Macular Degeneration (AMD) / AMD / Dry Macular Degeneration1
2TerminatedNot AvailableEpiretinal Membranes / Macular Holes1
2Unknown StatusTreatmentAge - Related Macular Degeneration (AMD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility10.4 mg/mLALOGPS
logP2.17ALOGPS
logP1.36Chemaxon
logS-1.4ALOGPS
pKa (Strongest Acidic)14.74Chemaxon
pKa (Strongest Basic)2.88Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area49.77 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity64.85 m3·mol-1Chemaxon
Polarizability26.92 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-05mo-9300000000-1b6c91b122dd716e7965
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4l-0970000000-d2817f0d0700c6b7ddaa
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-00di-0920000000-f93839cb12b532537d9f
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a59-9820000000-de68256fb87bcdd8d612
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0f79-9600000000-c22003daf137691ea1e3
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-00lr-9400000000-a6a6a37721765b1e2fa3
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0019-9400000000-0167d0341bf1f58c5fc2
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-155.07368
predicted
DeepCCS 1.0 (2019)
[M+H]+157.43169
predicted
DeepCCS 1.0 (2019)
[M+Na]+163.52484
predicted
DeepCCS 1.0 (2019)

Drug created at November 18, 2007 18:26 / Updated at June 12, 2020 16:52